MREO vs. ARWR

Last updated Aug 1, 2026

MREO (Mereo BioPharma Group plc) and ARWR (Arrowhead Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, MREO returned -33.17%/yr vs 4.09%/yr for ARWR. Their 0.28 correlation means their historical movements had little consistent relationship.

Performance

MREO vs. ARWR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Mereo BioPharma Group plc (MREO) and Arrowhead Pharmaceuticals, Inc. (ARWR). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, MREO achieves a -17.76% return, which is significantly lower than ARWR's 27.50% return.

MREO

• 1D: 8.79%
• 1M: 2.39%
• 6M: -22.11%
• YTD: -17.76%
• 1Y: -79.36%
• 3Y*: -36.68%
• 5Y*: -33.17%
• 10Y*: —
• ALL TIME*: -30.49%

ARWR

• 1D: -3.06%
• 1M: 0.79%
• 6M: 22.10%
• YTD: 27.50%
• 1Y: 431.39%
• 3Y*: 35.96%
• 5Y*: 4.09%
• 10Y*: 30.88%
• ALL TIME*: -0.69%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
ARWR Arrowhead Pharmaceuticals, Inc.	$205.45M	$188.79M	$175.31M
MREO Mereo BioPharma Group plc	$344.71K	$338.89K	$1.02M

MREO vs. ARWR - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
MREO Mereo BioPharma Group plc	-17.76%	-88.09%	51.52%	208.00%	-53.12%	-55.31%	9.15%	-31.95%
ARWR Arrowhead Pharmaceuticals, Inc.	27.50%	253.14%	-38.56%	-24.56%	-38.82%	-13.59%	20.97%	232.62%

Correlation

The correlation between MREO and ARWR is 0.21, which is low. Their historical price movements had little consistent relationship.

	Correlation
Correlation (1Y) Focuses on recent behavior, but can change the most.	0.21
Correlation (3Y) Balances recent behavior with more history.	0.27
Correlation (5Y) Shows whether the relationship held over a longer period.	0.32
Correlation (All Time) Calculated using the full available price history since Apr 24, 2019	0.28

The correlation between MREO and ARWR shifts across timeframes, from 0.21 (1 year) to 0.32 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap MREO : $54.70M ARWR : $11.92B
EPS MREO : -$0.22 ARWR : -$2.16
PS Ratio MREO : 109.61 ARWR : 19.00
PB Ratio MREO : 1.61 ARWR : 20.13
Total Revenue (TTM) MREO : $500.00K ARWR : $622.01M
Gross Profit (TTM) MREO : $366.00K ARWR : $529.27M
EBITDA (TTM) MREO : -$39.61M ARWR : -$168.38M

Return for Risk

MREO vs. ARWR — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

MREO

MREO Risk / Return Rank: 21
MREO Sharpe Ratio Rank: 16
MREO Sortino Ratio Rank: 34
MREO Omega Ratio Rank: 34
MREO Calmar Ratio Rank: 8
MREO Martin Ratio Rank: 14

ARWR

ARWR Risk / Return Rank: 99
ARWR Sharpe Ratio Rank: 100
ARWR Sortino Ratio Rank: 99
ARWR Omega Ratio Rank: 98
ARWR Calmar Ratio Rank: 100
ARWR Martin Ratio Rank: 100

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

MREO vs. ARWR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Mereo BioPharma Group plc (MREO) and Arrowhead Pharmaceuticals, Inc. (ARWR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	MREO	ARWR	Difference
Sharpe ratio: Return per unit of total volatility	-0.63	6.69	-7.32
Sortino ratio: Return per unit of downside risk	0.03	5.72	-5.70
Omega ratio: Gain probability vs. loss probability	1.00	1.70	-0.70
Calmar ratio: Return relative to maximum drawdown	-0.89	17.83	-18.72
Martin ratio: Return relative to average drawdown	-1.22	51.66	-52.88

MREO vs. ARWR - Sharpe Ratio Comparison

The current MREO Sharpe Ratio is -0.63, which is lower than the ARWR Sharpe Ratio of 6.69. The chart below compares the historical Sharpe Ratios of MREO and ARWR, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

MREO vs. ARWR - Drawdown Comparison

The maximum MREO drawdown since its inception was -96.35%, roughly equal to the maximum ARWR drawdown of -99.24%. Use the drawdown chart below to compare losses from any high point for MREO and ARWR.

Drawdown Indicators

	MREO	ARWR	Difference
Max Drawdown Largest peak-to-trough decline	-96.35%	-99.24%	+2.89%
Max Drawdown (1Y) Largest decline over 1 year	-89.73%	-24.64%	-65.09%
Max Drawdown (3Y) Largest decline over 3 years	-95.13%	-74.70%	-20.43%
Max Drawdown (5Y) Largest decline over 5 years	-95.13%	-87.89%	-7.24%
Max Drawdown (10Y) Largest decline over 10 years	—	-88.96%	—
Current Drawdown Current decline from peak	-94.73%	-47.91%	-46.82%
Average Drawdown Average peak-to-trough decline	-66.50%	-81.07%	+14.57%
Ulcer Index Depth and duration of drawdowns from previous peaks	65.21%	8.49%	+56.72%

Volatility

MREO vs. ARWR - Volatility Comparison

The current volatility for Mereo BioPharma Group plc (MREO) is 17.96%, while Arrowhead Pharmaceuticals, Inc. (ARWR) has a volatility of 23.10%. This indicates that MREO experiences smaller price fluctuations and is considered to be less risky than ARWR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	MREO	ARWR	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.96%	23.10%	-5.14%
Volatility (6M) Calculated over the trailing 6-month period	55.25%	39.03%	+16.22%
Volatility (1Y) Calculated over the trailing 1-year period	127.74%	65.63%	+62.11%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	100.61%	64.63%	+35.98%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	113.50%	74.38%	+39.12%

Dividends

MREO vs. ARWR - Dividend Comparison

Neither MREO nor ARWR has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both MREO and ARWR in my portfolio?

MREO and ARWR have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, MREO or ARWR?

ARWR has higher volatility (23.10%) compared to MREO (17.96%). In terms of maximum drawdown, MREO dropped -96.35% vs ARWR's -99.24%.

Which has better risk-adjusted returns?

ARWR currently has the higher Sharpe Ratio (6.69 vs -0.63), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.